ライフサイエンスコーパス: therapy for

1 riants were quantified at various times post-therapy for 14 days and a high-dimensional mathematical

2 after completion of non-surgical periodontal therapy for 213 sextants in 38 patients by two experienc

3 The administration of endocrine therapy for 5 years substantially reduces recurrence rat

4 treat osteoporotic women with pharmacologic therapy for 5 years.

5 sion and may ultimately inform the design of therapies for a broad range of mesenchymal cancers.

6 o the development of novel and more tailored therapies for a subset of medulloblastoma.

7 ise as a novel, exclusively oral combination therapy for a subset of high-risk DLBCL patients.

8 opterin monophosphate (cPMP) is a successful therapy for a subset of infants with MoCD and prevents i

9 stem cell transplantation may be a promising therapy for AATD-related liver disease.

10 iew the current evidence on nonpharmacologic therapies for acute or chronic nonradicular or radicular

11 e current evidence on systemic pharmacologic therapies for acute or chronic nonradicular or radicular

12 ant role for OxPAPC in inflammation offering therapy for acute and chronic inflammatory pain treatmen

13 We focused on patients who received DOAC therapy for acute HIT as either primary therapy (group A

14 anthracycline daunorubicin during induction therapy for acute myeloid leukemia (AML) have been shown

15 The first-line therapy for acute TTP is based on daily therapeutic plas

16 es evidence that supports the development of therapies for AD by targeting Abeta metabolism in both t

17 ugs and in the potential use of TNF-targeted therapies for AD.

18 rate clinical therapeutic efficacy from gene therapy for ADA-deficient SCID, with an excellent clinic

19 established autophagy activation as a novel therapy for ADPKD, and presented zebrafish as an efficie

20 nhibitors, such as vismodegib, are effective therapies for advanced BCCs.

21 Purpose To evaluate topotecan-based therapy for advanced intraocular retinoblastoma.

22 Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Eval

23 atients and 2 others completely discontinued therapy for adverse events.

24 atrial fibrillation has become an important therapy for AF; however, recurrence rates remain high.

25 mechanisms of ARS mutations toward designing therapies for affected patient populations.

26 des us with a paradigm in the development of therapies for aggressive MLL leukemia and perhaps for ot

27 els of lung disease and facilitate precision therapies for airway disorders such as cystic fibrosis.

28 ts older than 18 years treated with bridging therapy for AIS with LVO of the anterior circulation.

29 more effective behavior and pharmacological therapies for alcoholism.

30 rsies related to the implementation of novel therapies for all patients and set the scene as the fiel

31 These findings suggest that therapies for ALS may need to be tailored for different

32 Death within 1 year after initial therapy for AML.

33 apparent toxicity may help developing novel therapies for amyloid diseases.

34 underwent surgery but received no additional therapy for an American Joint Committee on Cancer stage

35 and thiazide-like diuretics as a first-line therapy for any outcome.

36 Caffeine therapy for apnea of prematurity did not significantly r

37 Caffeine citrate or placebo until drug therapy for apnea of prematurity was no longer needed.

38 The benefits of PPI therapy for appropriate indications need to be considere

39 The lack of success of pharmacological therapies for ARDS, however, presents a continued challe

40 Apixaban therapy for ARISTOTLE-eligible patients with atrial fibr

41 treatment of ASB and prolonged durations of therapy for ASB and symptomatic UTIs.

42 sidered the most effective anti-inflammatory therapy for asthma control and management; however, ther

43 Current therapies for autoimmune diseases rely on traditional im

44 essing B cells may be a potential target for therapy for autoimmune diseases.

45 rodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.

46 Lithium is a first-line therapy for bipolar affective disorder.

47 Targeted therapies for BL are therefore needed.

48 ommon than expected in centers providing BCG therapy for bladder cancer without adequate precautions.

49 e of CBCT imaging improving the execution of therapy for both types of defects.

50 5-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrasonography (US)

51 During the early decades of radiation therapy for breast cancer, local control of disease was

52 on of mTOR and is associated with everolimus therapy for breast cancer.

53 Targeted therapies for cancer are typically small molecules or mo

54 New targeted therapies for cancer have been released in recent years,

55 The design of effective therapies for cancer treatment depends on a comprehensiv

56 udy further supports Honokiol as a promising therapy for cancer patients receiving Dox treatment.

57 Pharmacological therapies for cardiovascular diseases are limited by sho

58 elaxin-2 (H2-RLX) has emerged as a potential therapy for cardiovascular and fibrotic diseases, but it

59 ture diagnostics, preventive strategies, and therapy for cardiovascular disease are reviewed.

60 tors, can be repurposed for TSP1 replacement therapy for CCMs.

61 Pharmacological treatment and antiarrhythmic therapy for ChHD is mostly based on results for other et

62 sult reporting and the duration of acyclovir therapy for children with signs and symptoms of meningit

63 l pressure (ICP) monitoring is a mainstay of therapy for children with traumatic brain injury (TBI),

64 ffects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of

65 of bacteriophages as a potential prophylaxis therapy for cholera, a severely dehydrating disease caus

66 ort Protein 1 is described as a part of gene therapy for choroideremia.

67 Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection

68 asia recommend intensive speech and language therapy for chronic (>/=6 months) aphasia after stroke,

69 e maintained and expanded to provide ongoing therapy for chronic infectious disease, there is a press

70 ne-kinase inhibitors could provide effective therapy for CML.

71 ly, there are no available disease-modifying therapies for CMML, nor are there preclinical models tha

72 tant implications for the development of new therapies for CNS injury and diseases.

73 the risk of CNVM development, and anti-VEGF therapy for CNVM was associated with better clinical out

74 the efficacy of clinically approved targeted therapies for commonly mutated BRAF(V600E) melanoma.

75 r profiles and the application of epigenetic therapies for CRC patient treatment.

76 Available systemic therapies for CTCL may variably decrease tumor burden an

77 s approach might be promising as co-adjuvant therapy for cystic fibrosis.

78 pathogenic mechanisms and for testing novel therapies for cystinosis.

79 (1-7) compounds and neprilysin inhibitors as therapies for diabetes.

80 Islet transplantation is an established therapy for diabetes.

81 effective deployment of rationally developed therapies for diffuse large B cell lymphoma (DLBCL) requ

82 oQ, alone and in combination with first line therapy for DKD.

83 While benzodiazepines are a first-line therapy for Dravet syndrome, they are limited by their a

84 Gene therapy for dry mouth disorders has transitioned in rece

85 t further investigation for development as a therapy for Duchenne or Becker muscular dystrophy.

86 durability and role of different endoscopic therapies for dysplastic Barrett's oesophagus.

87 cally assessed before starting the antiviral therapy for early detection and the improvement of the i

88 up of UR patients who also received adjuvant therapy-for early-stage resectable pancreatic adenocarci

89 There are no disease-modifying therapies for either FTD or NCL, in part because of a po

90 Cardiac transplantation is an effective therapy for end-stage heart failure.

91 combinatorial therapies to improve existing therapies for EOC patients.

92 velopment of new pharmacological and dietary therapies for epilepsy and other disorders.

93 Targeted therapies for ER+/PR+ and HER2-amplified breast cancers

94 re, reexpression of PTPRO may be a potential therapy for ERBB2-overexpressing breast cancer.

95 prevented altogether, based on the choice of therapy for FL.

96 support the concept of progranulin-boosting therapies for frontotemporal dementia and highlight an i

97 op codons (PTCs) is a potentially attractive therapy for genetic disorders, but a wide outcome variab

98 ecular approaches for cell replacement-based therapies for glaucoma and other optic neuropathies.SIGN

99 Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for developmental

100 ced an evidence-based guideline on radiation therapy for glioblastoma.

101 s were eligible if they received combination therapy for >/=48 hours.

102 Thus, BocaSR may be a target for antiviral therapies for HBoV and may also have utility in the prod

103 itizes cancer cells to sorafenib, a targeted therapy for HCC.

104 ex auditory function, may enable future gene therapies for hearing and balance disorders.

105 the major obstacles in the prevention of and therapy for heart disease.

106 splantation (HSCT) is a critically important therapy for hematological malignancies, inborn errors of

107 New therapies for hemophilia A and hemophilia B will likely

108 mphasis on titration of proven neurohormonal therapies for HF.

109 Current management and therapy for HF in children are extrapolated from treatme

110 host factors, traditional risk factors, and therapies for HIV.

111 will accelerate the development of targeted therapies for human cancer harboring mutp53.

112 ship can be exploited for the development of therapies for human cleft palates that arise from single

113 o eye movements might help in designing drug therapies for human eye movement dysfunctions such as ab

114 Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-ove

115 d generally be included in the pharmacologic therapy for hypertension in patients with Type 2 diabete

116 uction of lactoferrin to present a potential therapy for ICH.

117 ternative medicines (CAMs), or nonallopathic therapies, for inflammatory bowel diseases (IBDs).

118 Although cognitive behavior therapy for insomnia (CBT-I) has been established as the

119 s with lorcaserin may provide the first ever therapy for intensive care unit acquired weakness in pat

120 Purpose Adjuvant therapy for intermediate-risk and high-risk localized pr

121 ke risk include medical androgen deprivation therapy for ischemic and any stroke and erectile dysfunc

122 ffectiveness of cardiac stem/progenitor cell therapy for ischemic heart disease.

123 ge because of the lack of effective targeted therapy for its treatment.

124 sfer in adult mice are needed to develop new therapies for kidney disease.

125 There are currently no effective targeted therapies for KRAS mutant cancers.

126 drial uncoupling agents as a potential novel therapy for lipodystrophy-associated hypertriglyceridemi

127 ted scenarios, SBRT was preferred as salvage therapy for local progression after RFA.

128 riants may facilitate the development of new therapies for lowering TRL levels.

129 tase inhibitors (statins) have been the main therapy for lowering LDL-C.

130 ty of catheter ablation over pharmacological therapy for maintenance of sinus rhythm in patients with

131 cell transplantation is a potential curative therapy for malignant and nonmalignant diseases.

132 tumor cell invasion may provide an effective therapy for malignant glioma.

133 treatment may be developed into a potential therapy for malignant glioma.

134 Effective therapies for managing melanoma are limited, so we sough

135 immunosuppression may be a preferred initial therapy for many noninfectious, intermediate, posterior,

136 Current therapies for medulloblastoma were introduced primarily

137 BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutati

138 In a mouse model of adoptive T cell therapy for melanoma, Runx3-deficient CD8(+) tumour-infi

139 iotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical be

140 of all human cancer types with no effective therapy for metastatic disease.

141 Systemic therapy for metastatic melanoma has evolved rapidly duri

142 linical trials of immune checkpoint blockade therapy for metastatic melanoma, we found that tumor ane

143 CAR-T therapies for MM are at an early stage of development bu

144 Use of systemic therapies for moderate to severe psoriasis in children i

145 hout bone sarcoma and those able to tolerate therapy for more than 3 cycles (9 weeks) benefit.

146 leus (STN) is a highly effective symptomatic therapy for motor deficits in Parkinson's disease (PD).

147 This study explores a potential therapy for MPS-I at a very early stage in life and repr

148 ng new strategies for "step-down" antibiotic therapy for MRSA-BSI; (4) management of staphylococcal B

149 ic DCs can be engineered for myelin-specific therapy for MS.

150 ility treatment or mitochondrial replacement therapy for mtDNA disease.

151 Proteasome inhibition is an effective therapy for multiple myeloma (MM) patients; however, the

152 cumulation and gain-of-function and targeted therapies for mutp53 in human cancer.

153 Available therapies for myelofibrosis can exacerbate cytopenias an

154 y and efficacy profile of E10030 combination therapy for nAMD was evident across multiple clinically

155 eived antivascular endothelial growth factor therapies for neovascular AMD had decreased mortality co

156 ptical coherence tomography (OCT) in guiding therapy for neovascular age-related macular degeneration

157 ts on all-cause mortality after radiopeptide therapy for neuroendocrine tumors (NETs).

158 Targeted therapy for neuropsychiatric disorders requires selectiv

159 (CSs) and cyclosporine A (CsA) as first-line therapy for newly diagnosed cGVHD after allo-SCT.

160 response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 2

161 al, testing enhancement of immune checkpoint therapy for NSCLC.

162 tion nivolumab plus ipilimumab as first-line therapy for NSCLC.

163 is on the development of microbiome-targeted therapies for obesity prevention and treatment.

164 dge of the risks and benefits of alternative therapies for obesity.

165 though organ transplantation is an effective therapy for older patients (i.e., older than 65 years of

166 anti-epidermal growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory ef

167 Bisphosphonates are the frontline therapy for osteoporosis, which act by reducing bone rem

168 more precise and personalized allocation of therapy for our cardiovascular patients.

169 was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and murine m

170 motherapy, the most widely used single-agent therapy for pancreatic cancer.

171 urvival outcome after resection and adjuvant therapy for pancreatic cancer.

172 imization, this approach may enable clinical therapies for Parkinson's disease by delivery of genes r

173 increasing TGF-beta signaling as a potential therapy for Parkinson's disease.

174 ation (soft tissue and/or bone augmentation) therapies for patients undergoing orthodontic tooth move

175 tion devices are effective and commonly used therapies for patients with cardiac rhythm disorders.

176 ascular events, despite the efficacy of many therapies for patients with heart failure with reduced e

177 most mammary cancers, there are no targeted therapies for patients with TNBC.

178 ion presents a challenge when developing new therapies for patients.

179 framework for future tailoring, triage, and therapy for patients in a more personalized and precise

180 rker established for selection of a specific therapy for patients with advanced gastroesophageal aden

181 and Drug Administration-approved first-line therapy for patients with advanced hepatocellular carcin

182 dvances and provides suggestions to optimize therapy for patients with BOS after HCT.

183 and other bone-modifying agents as adjuvant therapy for patients with breast cancer.

184 gists is central to defining the appropriate therapy for patients with cancer.

185 clinical trial extends the reach of TCR gene therapy for patients with metastatic cancer.

186 reatment regimen as an adjunct antivirulence therapy for patients with MRSA infections.

187 and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.

188 aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are

189 updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung c

190 ) inhibitor ruxolitinib is the only approved therapy for patients with symptomatic myelofibrosis.

191 Gene therapy for patients with this disorder is complicated b

192 of developing new PAI-1- and CCL5-targeting therapy for patients with TNBC.

193 t efforts toward the development of targeted therapies for PD and related synucleinopathies.

194 f antibacterial prophylaxis during induction therapy for pediatric ALL and the first to include a bro

195 and have implications for the development of therapies for peripheral diabetic neuropathy.

196 In recent years, short-term antiviral therapy for pregnant women in the third trimester has be

197 need for developing clinically translatable therapy for preventing fetal origins of cardiovascular d

198 The review did not address hormone therapy for preventing or treating menopausal symptoms.

199 oral anticoagulation therapy is the standard therapy for preventing thromboembolic events in patients

200 supplementation with I3C is a potential new therapy for prevention and amelioration of C. difficile

201 , and greater utilization of optimal medical therapy for prevention and treatment of CAD.

202 we searched MEDLINE for randomized trials of therapies for primary or secondary cardiovascular preven

203 topoietic stem cell transplantation and gene therapy for primary immunodeficiency have had relative s

204 elective laser trabeculoplasty (SLT) as sole therapy for primary open-angle glaucoma (POAG) in an Afr

205 ciation recommendations on initiating statin therapy for primary prevention of ASCVD (net 221 individ

206 Effective therapies for progressive multiple sclerosis that preven

207 velopment into a safe and potent alternative therapy for prostate cancer patients.

208 eter-based, transvenous phrenic nerve pacing therapy for protecting the diaphragm in sedated and vent

209 ut the drug survival of second-line biologic therapies for psoriasis in routine clinical practice.

210 inib and IL36alpha siRNA as a potential dual therapy for psoriasis.

211 fore helping to develop new mechanisms-based therapies for psychiatric disorders.SIGNIFICANCE STATEME

212 e sensitive to detect response to antibiotic therapy for pulmonary exacerbations.

213 Advanced therapies for pump failure or refractory VAs, including

214 proof of principle for an epigenetics-based therapy for PWS.

215 g sequences for molecule-based diagnosis and therapy for ragweed allergy.

216 ecades ago, but there are still no effective therapies for Ras-driven cancers.

217 transplantation (FMT) is a highly effective therapy for recurrent Clostridium difficile infection (C

218 ing AS activity in these mice is a promising therapy for reducing hypertension.

219 atrox venom (Cv-PC) as potential preventive therapy for reducing perioperative hemorrhage in the rod

220 RATIONALE: New therapies for refractory angina are needed.

221 th chimeric antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leuk

222 occurred in 46% of patients following T cell therapy for relapsed/refractory acute lymphoblastic leuk

223 drug effects will enable improvements in MSC therapies for renal disease.

224 tigation of this compound as a novel adjunct therapy for reperfusion injury.

225 sDLCs could represent a promising adjunctive therapy for restoring iodide avidity within the full spe

226 entions represent a novel class of potential therapies for retinal diseases, such as age-related macu

227 damage and may have importance in designing therapies for retinal protection.

228 mine the effectiveness of PR3 as a potential therapy for RP, we treated Rho(P23H) mice with PR3 and a

229 h RV devices grows, their role as mechanical therapies for RV failure will depend less on the technic

230 dime/avibactam plus aztreonam as combination therapy for S. maltophilia infections and confirm that a

231 The path to new therapies for schizophrenia and bipolar illness.

232 em development and serve as a potential cell therapy for SCI.

233 The lack of effective therapies for SEB exposure remains an area of concern, p

234 isation therapy, and the use of endovascular therapies for secondary prevention, which, so far, have

235 SCVD with or without comorbidities on statin therapy for secondary prevention.

236 ental evidence that ivacaftor is a potential therapy for selected patients who harbor mutations in th

237 he PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examine

238 lymphoma, it could potentially be used as a therapy for skin diseases like psoriasis, where AQP3 is

239 Effective targeted therapies for small-cell lung cancer (SCLC), the most ag

240 cacy of a novel gaze-contingent music reward therapy for social anxiety disorder designed to reduce a

241 ese molecules are moving towards a potential therapy for spinal muscular atrophy (SMA).

242 development of brexanolone as an adjunctive therapy for SRSE requiring pharmacological coma for seiz

243 Therapy for steroid-refractory acute graft-versus-host d

244 ntial as an autologous, multifunctional cell therapy for stroke, which is the primary cause of long t

245 atic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infections (UTIs),

246 of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC.

247 and PI3K pathway inhibitors as a combination therapy for targeting breast cancer.

248 pies may be useful adjunctive, host-directed therapies for TB.

249 ective and clinically relevant host-directed therapy for TB.

250 luated the following 3 widely used empirical therapies for the ability to reduce the severity of para

251 chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic conditions

252 There are no specifically approved targeted therapies for the most common genomically defined subset

253 f the potential benefits of helminth-derived therapies for the prevention or treatment of allergic an

254 Such conjugates are potential therapies for the treatment of bone disorders such as os

255 n providing new and transformative analgesic therapies for the treatment of chronic pain.

256 rocytes is therefore critical for developing therapies for the treatment of MS.

257 ate the development of age-tailored targeted therapies for the treatment of pediatric AML.

258 cer has raised questions about optimal local therapy for the axilla.

259 ed placebo-controlled trials of antiplatelet therapy for the prevention of ischemic events in stable

260 ed as a valid alternative to anticoagulation therapy for the prevention of stroke/systemic embolism i

261 ommendation on the use of menopausal hormone therapy for the primary prevention of chronic conditions

262 ng the use of intravenous and oral antiviral therapy for the treatment of ARN.

263 in should be further explored as an adjuvant therapy for the treatment of glioblastoma.

264 n approved in combination with hormone-based therapy for the treatment of naive hormone receptor-posi

265 rowth, will undoubtedly yield more effective therapies for these cancer predisposition syndromes.

266 teric neural stem cells (ENSC) is a possible therapy for these life-limiting disorders.

267 rt the further investigation of immune-based therapies for this cancer.

268 a lack of biomarkers and effective targeted therapies for this disease.

269 evelops, designing timely and truly targeted therapies for this syndrome requires identification of k

270 ng chromatin regulators in cancer, available therapies for this well-characterized disease remain ina

271 liver injury in mice and may be an effective therapy for this and other forms of human liver disease.

272 al concepts that will lead to a more refined therapy for this tumour type.

273 very of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.

274 ) is a life-saving form of renal replacement therapy for those with end-stage kidney disease.

275 ial treatment strategies focused on ablative therapy for threshold ROP, earlier treatment for type 1

276 behavior and offering customized cell-based therapies for tissue engineering.

277 implications toward developing an effective therapy for TNBC.

278 to transplantation (BTT), and as definitive therapy for toxic ingestion or idiopathic liver failure

279 and highlights the need to develop targeted therapies for transcription factors.

280 ajor limitation in the study of testosterone therapy for transgender men is a paucity of high-quality

281 into allograft rejection and lead to better therapies for transplant patients.

282 vivo Treg induction could also enable novel therapies for transplant rejection and autoimmune diseas

283 erve as a basis for future PI3K-based immune therapies for transplantation.Phosphatidylinositol-3-kin

284 analysis to quantify benefits of hypothermia therapy for traumatic brain injuries in adults and child

285 e of death remains unknown, and no effective therapies for treating fulminant pertussis exist.

286 encephalopathy, and searching for potential therapies for treating pathologic hyperbilirubinemia.

287 Adenosine, the standard therapy for treating supraventricular tachycardia in chi

288 esenchymal stem cells (hMSCs) is an emerging therapy for treating the failing heart.

289 New biological therapies for treatment of severe asthma, together with

290 improved patient survival, but there are no therapies for triple negative breast cancers (TNBC) that

291 re the first results supporting AKT-targeted therapy for triple-negative breast cancer.

292 t's clinical status and the lack of targeted therapies for TSS emphasize the need to identify key pla

293 ent, and ultimately safer and more effective therapies for tuberculosis.

294 d model to predict the response to anti-VEGF therapy for tumors expressing different levels of VEGF r

295 tes, reduces unnecessary therapy but permits therapy for ventricular tachycardia/ventricular fibrilla

296 total of 215 patients underwent endovascular therapy for vertebrobasilar occlusion strokes during the

297 ly functioning ICDs failed to deliver timely therapy for VF from April 2015 to January 2017 at 4 inst

298 The first attempts at gene therapy for WAS using a Upsilon-retroviral vector improv

299 Twenty patients received systemic therapy for widely disseminated disease.

300 Parenteral antibiotic therapy for young infants (aged 0-59 days) with suspecte